Claims for Patent: 8,722,619

Summary for Patent: 8,722,619

Title:	Antifungal agents and uses thereof
Abstract:	The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.
Inventor(s):	Kenneth Duke James, JR., Christopher Patrick Laudeman
Assignee:	NAPP PHARMACEUTICAL GROUP Ltd
Application Number:	US13/886,972
Patent Claims:	1. A compound having the formula: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein said compound is an acetate salt. 3. The compound of claim 1, wherein said compound is a chloride salt. 4. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 5. The pharmaceutical composition of claim 4, wherein said compound is an acetate salt. 6. The pharmaceutical composition of claim 4, wherein said compound is a chloride salt. 7. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for oral administration. 8. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for intravenous administration. 9. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for topical administration. 10. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for subcutaneous administration. 11. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for inhalation. 12. A method of treating a fungal infection in a subject, said method comprising administering to said subject a pharmaceutical composition of claim 4 in an amount sufficient to treat said infection. 13. The method of claim 12, wherein said pharmaceutical composition is administered orally. 14. The method of claim 12, wherein said pharmaceutical composition is administered intravenously. 15. The method of claim 12, wherein said pharmaceutical composition is administered topically. 16. The method of claim 12, wherein said pharmaceutical composition is administered subcutaneously. 17. The method of claim 12, wherein said pharmaceutical composition is administered by inhalation. 18. The method of claim 12, wherein said pharmaceutical composition is administered to treat a blood stream infection or tissue infection in said subject. 19. The method of claim 12, wherein said infection is selected from tinea capitis, tinea corporis, tinea pedis, onychomycosis, perionychomycosis, pityriasis versicolor, oral thrush, vaginal candidosis, respiratory tract candidosis, biliary candidosis, eosophageal candidosis, urinary tract candidosis, systemic candidosis, mucocutaneous candidosis, aspergillosis, mucormycosis, paracoccidioidomycosis, North American blastomycosis, histoplasmosis, coccidioidomycosis, sporotrichosis, fungal sinusitis, or chronic sinusitis. 20. The method of claim 12, wherein said fungal infection is an infection of Candida albicans, C. parapsilosis, C. glabrata, C. guilliermondii, C. krusei, C. tropicalis, C. lusitaniae, Aspergillus fumigatus, A. flavus, A. terreus, A. niger, A. candidus, A. clavatus, or A. ochraceus. 21. A method of inhibiting the growth of fungi, or killing fungi, said method comprising contacting said fungi with the compound of claim 1, or a pharmaceutically acceptable salt thereof.